

# 2025 Current Fiscal Year Report: Medical Imaging Drugs Advisory Committee

Report Run Date: 04/25/2026 01:51:21 AM

## 1. Department or Agency

Department of Health and Human Services

## 2. Fiscal Year

2025

## 3. Committee or Subcommittee

Medical Imaging Drugs Advisory Committee

## 3b. GSA Committee No.

917

## 4. Is this New During Fiscal Year? 5. Current Charter 6. Expected Renewal Date 7. Expected Term Date

No 05/18/2023 05/18/2025

## 8a. Was Terminated During Fiscal Year? 8b. Specific Termination Authority 8c. Actual Term Date

Yes Per Agency Head 05/19/2025

## 9. Agency Recommendation for Next Fiscal Year 10a. Legislation Req to Terminate? 10b. Legislation Pending?

Terminate Not Applicable Not Applicable

## 11. Establishment Authority Authorized by Law

## 12. Specific Establishment Authority 13. Effective Date 14. Committee Type 14c. Presidential?

21 U.S.C. 394 11/28/1990 Continuing No

## 15. Description of Committee Scientific Technical Program Advisory Board

## 16a. Total Number of Reports

No Reports for this Fiscal Year

## 17a. Open 17b. Closed 17c. Partially Closed 17d. Total

## Meetings and Dates

No Meetings

	<b>Current FY</b>	<b>Next FY</b>
<b>18a(1). Personnel Pmts to Non-Federal Members</b>	\$0.00	\$0.00
<b>18a(2). Personnel Pmts to Federal Members</b>	\$0.00	\$0.00
<b>18a(3). Personnel Pmts to Federal Staff</b>	\$61,802.00	\$0.00
<b>18a(4). Personnel Pmts to Non-Member Consultants</b>	\$0.00	\$0.00
<b>18b(1). Travel and Per Diem to Non-Federal Members</b>	\$0.00	\$0.00
<b>18b(2). Travel and Per Diem to Federal Members</b>	\$0.00	\$0.00
<b>18b(3). Travel and Per Diem to Federal Staff</b>	\$0.00	\$0.00
<b>18b(4). Travel and Per Diem to Non-member Consultants</b>	\$0.00	\$0.00
<b>18c. Administrative Costs (FRNs, contractor support, In-person/hybrid/virtual meetings)</b>	\$0.00	\$0.00
<b>18d. Other (all other funds not captured by any other cost category)</b>	\$15,451.00	\$0.00
<b>18e. Total Costs</b>	\$77,253.00	\$0.00
<b>19. Federal Staff Support Years (FTE)</b>	0.35	0.00

**20a. How does the Committee accomplish its purpose?**

The Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the

Commissioner of Food and Drugs.

**20b. How does the Committee balance its membership?**

Members are authorities in the fields of nuclear medicine, radiology, epidemiology or statistics, and related specialties. The committee includes one technically qualified voting member who is identified with consumer interests. The Committee may include one non-voting member who is identified with industry interests.

**20c. How frequent and relevant are the Committee Meetings?**

The Committee did not meet during FY-25.

**20d. Why can't the advice or information this committee provides be obtained elsewhere?**

Members of the Committee are drawn from academia, research and/or clinical practice. Their advice and input are considered by FDA as part of its regulatory decision-making process. The alternate means of obtaining this advice would involve the recruitment of large numbers of scientists on a full-time basis at a maximum rate of compensation.

**20e. Why is it necessary to close and/or partially closed committee meetings?**

The Committee held no closed meetings during FY-25.

**21. Remarks**

Per Agency Head

**Designated Federal Officer**

Takyiah Stevenson Designated Federal Officer

Committee Members	Start	End	Occupation	Member Designation
-------------------	-------	-----	------------	--------------------

Applegate, Kimberly	07/30/2015	05/18/2025	Professor of Radiology and Pediatrics (retired)	Special Government Employee (SGE) Member
Herscovitch, Peter	07/30/2015	05/18/2025	Department Director, PET Department, National Institutes of Health	Regular Government Employee (RGE) Member
Larson, Steven	01/08/2024	05/18/2025	Emeritus Member, Department of Radiology and Molecular Pharmacology Memorial Sloan Kettering Cancer Center	Special Government Employee (SGE) Member
Rosenthal, Eben	07/01/2021	05/18/2025	Professor and Chair, Department of Otolaryngology, Vanderbilt University Medical Center	Special Government Employee (SGE) Member
Sanghani, Rupa	07/01/2021	01/01/2025	Associate Professor of Medicine, Director of Nuclear Cardiology, Rush University Medical Center	Special Government Employee (SGE) Member
Xiong, Chengjie	09/24/2019	05/18/2025	Professor of Biostatistics and Neurology Division of Biostatistics & Department of Neurology Washington University	Special Government Employee (SGE) Member

## Number of Committee Members Listed: 6

### Narrative Description

FDA's strategic priorities in responding to the public health challenges of the 21st century are to advance regulatory science and innovation; strengthen the safety and integrity of the global supply chain; strengthen compliance and enforcement activities to support public health; expand efforts to meet the needs of special populations; advance medical countermeasures and emergency preparedness; advance food safety and nutrition; promote public health by advancing the safety and effectiveness of medical products; establish an effective tobacco regulation, prevention, and

control program; and manage for organizational excellence and accountability. The Medical Imaging Drugs Advisory Committee reviews and evaluates data concerning the safety and effectiveness of marketed and investigational human drug products for use in diagnostic and therapeutic procedures using radioactive pharmaceuticals and contrast media used in diagnostic radiology and makes appropriate recommendations to the Commissioner of Food and Drugs. This supports the development of safe and effective new medical technologies and advances the status of the Agency as a science-based and science-led regulatory agency, providing global leadership in the protection of public health.

**What are the most significant program outcomes associated with this committee?**

Checked if  
Applies

- Improvements to health or safety
- Trust in government
- Major policy changes
- Advance in scientific research
- Effective grant making
- Improved service delivery
- Increased customer satisfaction
- Implementation of laws or regulatory requirements
- Other

**Outcome Comments**

N/A

**What are the cost savings associated with this committee?**

Checked if Applies

- None
- Unable to Determine
- Under \$100,000
- \$100,000 - \$500,000
- \$500,001 - \$1,000,000
- \$1,000,001 - \$5,000,000

\$5,000,001 - \$10,000,000



Over \$10,000,000



Cost Savings Other



### **Cost Savings Comments**

The utilization of the Medical Imaging Drugs Advisory Committee enabled the Agency to obtain required and frequently scarce professional services from medical and scientific experts not otherwise available to the Agency; and to obtain the services of these experts only on an as needed basis rather than on a full-time basis. The service of the Committee resulted in advice for the improvement of the public health, for which it is difficult to assign a financial value.

**What is the approximate Number of recommendations produced by this committee for the life of the committee?**

6

### **Number of Recommendations Comments**

The Committee made 6 recommendations from FY-03 through the FY-25.

**What is the approximate Percentage of these recommendations that have been or will be Fully implemented by the agency?**

84%

### **% of Recommendations Fully Implemented Comments**

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, therefore, the Agency has the option of not implementing the advice. This number represents an approximation of the percentage of recommendations that the agency has fully implemented or plans to fully implement.

**What is the approximate Percentage of these recommendations that have been or will be Partially implemented by the agency?**

10%

### **% of Recommendations Partially Implemented Comments**

The function of an advisory committee is purely advisory in nature. Although the FDA most often accepts the recommendations from its committees, the advice is purely advisory in nature, and therefore, the Agency has the option of not implementing the advice.

**Does the agency provide the committee with feedback regarding actions taken to implement recommendations or advice offered?**

Yes  No  Not Applicable

**Agency Feedback Comments**

When appropriate, information is made available to the public. Actions related to guidance documents or other general matters issues are available publicly when implemented.

**What other actions has the agency taken as a result of the committee's advice or recommendation?**

Checked if Applies

Reorganized Priorities	<input checked="" type="checkbox"/>
Reallocated resources	<input type="checkbox"/>
Issued new regulation	<input checked="" type="checkbox"/>
Proposed legislation	<input type="checkbox"/>
Approved grants or other payments	<input type="checkbox"/>
Other	<input checked="" type="checkbox"/>

**Action Comments**

FDA approves or chooses not to approve a new medical product.

**Is the Committee engaged in the review of applications for grants?**

No

**Grant Review Comments**

N/A

**How is access provided to the information for the Committee's documentation?**

Checked if Applies

Contact DFO	<input checked="" type="checkbox"/>
Online Agency Web Site	<input checked="" type="checkbox"/>
Online Committee Web Site	<input checked="" type="checkbox"/>
Online GSA FACA Web Site	<input checked="" type="checkbox"/>
Publications	<input checked="" type="checkbox"/>
Other	<input type="checkbox"/>

**Access Comments**

NA